MMR Vaccination in Patients with History of Breast Cancer and Hodgkin Lymphoma
Patients with a history of breast cancer and Hodgkin lymphoma who have completed chemotherapy for at least 3 months and are not currently on immunosuppressive therapy should receive MMR vaccine.
Key Decision Points
Current Treatment Status is Critical
The decision hinges entirely on whether the patient is currently receiving immunosuppressive therapy:
- If NOT currently immunosuppressed: MMR vaccine should be administered 1, 2
- If currently on chemotherapy or within 3 months of completion: MMR vaccine is contraindicated 3, 4, 1, 5
Timing After Chemotherapy Completion
Wait at least 3 months after chemotherapy ends before administering MMR vaccine 3, 4, 1. The 2014 IDSA guideline specifically states: "Three months after cancer chemotherapy, patients should be vaccinated with...the live vaccines for...measles, mumps, and rubella" 1. For regimens that included anti-B-cell antibodies (rituximab), delay vaccination for at least 6 months 1.
Why This Matters for Your Patient
Patients with hematologic malignancies like Hodgkin lymphoma are at particularly high risk of losing pre-existing MMR immunity during chemotherapy. Studies show that 27% lose measles immunity, 47% lose mumps immunity, and 19% lose rubella immunity after cancer treatment 6. The loss is even more pronounced in patients with hematologic malignancies compared to solid tumors like breast cancer 6.
Absolute Contraindications
MMR vaccine must NOT be given if the patient 5:
- Is currently receiving chemotherapy or immunosuppressive therapy
- Has severe immunosuppression from disease or treatment
- Completed chemotherapy less than 3 months ago
- Is on high-dose corticosteroids (≥20 mg/day prednisone or ≥2 mg/kg/day for ≥14 days)
The FDA label explicitly states: "Do not administer M-M-R II vaccine to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy" 5. Fatal disseminated measles vaccine virus infections have been reported in severely immunocompromised individuals 3, 5.
Clinical Algorithm
Step 1: Determine current immunosuppression status
- Currently on chemotherapy or immunosuppressive therapy? → Do NOT vaccinate
- Completed chemotherapy ≥3 months ago (≥6 months if rituximab)? → Proceed to Step 2
Step 2: Assess for other contraindications
- Active fever >101.3°F? → Defer until resolved 5
- Pregnant or planning pregnancy within 1 month? → Do NOT vaccinate 5
- History of anaphylaxis to vaccine components (gelatin, neomycin)? → Do NOT vaccinate 5
Step 3: If no contraindications exist → Administer MMR vaccine
Important Caveats
Immunity Loss is Common and Progressive
Research demonstrates that over 75% of childhood cancer survivors who received MMR before their cancer diagnosis had negative or equivocal titers to measles or mumps years later 7. Importantly, measles seronegativity increases with longer intervals since chemotherapy (>5 years) 8. This underscores the importance of revaccination after treatment completion.
Two-Dose Series Recommended
If the patient received MMR vaccines before their cancer diagnosis, those doses may not provide long-term protection. The most recent evidence shows that all cancer survivors who received the complete MMR series AFTER completing cancer treatment demonstrated long-term seroprotection at a mean of 8.2 years post-vaccination 7. Therefore, consider administering a complete 2-dose series starting 3 months after chemotherapy completion, regardless of prior vaccination history.
Household Contacts Should Be Vaccinated
Close contacts and household members should receive MMR vaccine to create a protective cocoon around the patient 3, 9. MMR vaccine is safe to administer to household contacts even when the patient is immunocompromised, as vaccine strain transmission is not associated with MMR 9.
Corticosteroid Considerations
Low-dose or short-term corticosteroids do not contraindicate MMR vaccination. The threshold for concern is prednisone ≥20 mg/day or ≥2 mg/kg/day for ≥14 days 3. Wait at least 1 month after stopping high-dose steroids before vaccinating 3.
Bottom Line
For a patient with completed treatment for both breast cancer and Hodgkin lymphoma who is not currently immunosuppressed, MMR vaccination is both safe and strongly recommended starting 3 months after chemotherapy completion. The substantial risk of immunity loss during cancer treatment, combined with the safety profile of MMR in non-immunosuppressed cancer survivors, makes revaccination a critical component of survivorship care 1, 2, 10.